Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

INOVIO Expands Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization

10/11/2021 | 08:00am EST

Inovio Pharmaceuticals, Inc. announced that it has received authorization from Colombia'sINVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos, or the National Food and Drug Surveillance Institute), to conduct the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy) in Colombia, for INO-4800, its DNA vaccine candidate for COVID-19. INOVIO is working with partner Advaccine Biopharmaceuticals Suzhou Co. Ltd. (Advaccine) on the INNOVATE Phase 3 segment in multiple countries, with a focus on countries in Latin America, Asia, and Africa. INOVIO recently announced that it has received regulatory authorization to proceed in Brazil, Philippines, and Mexico. The global Phase 3 segment of INNOVATE will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart, in a 2-to-1 randomization in men and non-pregnant women 18 years of age and older. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed COVID-19.


© S&P Capital IQ 2021
All news about INOVIO PHARMACEUTICALS, INC.
11/26Novavax developing vaccine that targets new COVID-19 variant
RE
11/16Inovio Pharmaceuticals Begins Dosing in Phase 1 Trial of Ebola Vaccine
MT
11/16INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Boost..
PR
11/16INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Boost..
CI
11/15INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference
PR
11/09Earnings Flash (INO) INOVIO PHARMACEUTICALS Posts Q3 Revenue $291.7M
MT
11/09INOVIO : Q3 Earnings Snapshot
AQ
11/09INOVIO Reports Third Quarter 2021 Financial Results
PR
11/09INOVIO PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
11/09Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 3,47 M - -
Net income 2021 -262 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,72x
Yield 2021 -
Capitalization 1 525 M 1 525 M -
Capi. / Sales 2021 439x
Capi. / Sales 2022 13,6x
Nbr of Employees 262
Free-Float 98,4%
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 7,25 $
Average target price 13,00 $
Spread / Average Target 79,3%
EPS Revisions
Managers and Directors
J. Joseph Kim President, Chief Executive Officer & Director
Peter D. Kies Chief Financial Officer
Simon X. Benito Chairman
Laurent M. Humeau Chief Scientific Officer
Kate E. Broderick Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
INOVIO PHARMACEUTICALS, INC.-18.08%1 525
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431